Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

223.43 +4.41 (+2.01%)

Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

86 87 Next >

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal ↗

February 05, 2026

Via MarketBeat

ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds

February 05, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 6% year on year to $16 billion. Its non-GAAP profit of $2.71 per share was 2.2% above...

Via StockStory

AbbVie Inc. (NYSE:ABBV) Raises 2026 Outlook Despite Q4 Revenue Miss ↗

February 04, 2026

Via Chartmill

AbbVie (ABBV) Q4 2025 Earnings Call Transcript ↗

February 04, 2026

AbbVie (ABBV) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Gapping S&P500 stocks in Wednesday's session ↗

February 04, 2026

Via Chartmill

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

February 04, 2026

Via Chartmill

AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue

February 04, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10% year on year to $16.62 billion. Its non-GAAP profit of $2.71 per...

Via StockStory

2 Healthcare Dividend Stocks That are Just What the Doctor Ordered ↗

February 03, 2026

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.

Via The Motley Fool

Topics Intellectual Property

AbbVie (ABBV) Q4 Earnings: What To Expect

February 02, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Wednesday before market open. Here’s what to expect.

Via StockStory

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Where Will AbbVie Be in 5 Years? ↗

February 02, 2026

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

Via The Motley Fool

Topics Intellectual Property

2 No-Brainer Dividend Stocks to Buy Hand Over Fist ↗

February 01, 2026

They are great long-term options.

Via The Motley Fool

Topics Economy Intellectual Property

Better Long-Term Buy: This Emerging Player or the Industry Leader? ↗

January 30, 2026

The choice between the two might come down to each investor's goals and risk tolerance.

Via The Motley Fool

Topics Intellectual Property

Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

January 28, 2026

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.

Via StockStory

Topics Artificial Intelligence

Why AbbVie Stock Trounced the Market in 2025 ↗

January 28, 2026

The company sure knows what to do before and after a blockbuster drug tumbles off the patent cliff.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 27, 2026

In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx...

Via MarketMinute

Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗

January 26, 2026

It doesn't look like the company will end up in the arms of an acquirer soon, after all.

Via The Motley Fool

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

The Best Dividend Stocks to Buy and Hold Forever ↗

January 26, 2026

These stocks offer highly attractive dividends and staying power.

Via The Motley Fool

Topics Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly

January 23, 2026

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...

Via Finterra

Topics Intellectual Property

2 High-Yielding Dividend Stocks That Retirees Can Rely on for Recurring Income ↗

January 22, 2026

These stocks offer yields of more than double the S&P 500 average.

Via The Motley Fool

Topics Stocks

My Top 4 Stocks to Buy in Early 2026 ↗

January 22, 2026

These stocks offer impressive long-term upside with downside protection.

Via The Motley Fool

Topics Artificial Intelligence Economy

The Titan’s Balance: Johnson & Johnson Reaches Record Highs Amidst Legal Hurdles and Med-Tech Transformation

January 20, 2026

As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On...

Via MarketMinute

Topics Bankruptcy Lawsuit World Trade

1 Safe-and-Steady Stock on Our Watchlist and 2 We Find Risky

January 19, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever ↗

January 19, 2026

All three of these healthcare giants are leaders in their niches.

Via The Motley Fool

Topics Artificial Intelligence

3 “Forever Stocks” to Hold When the Market Won’t Sit Still ↗

January 19, 2026

Via MarketBeat

The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature

January 19, 2026

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its...

Via Finterra

Topics Artificial Intelligence Bankruptcy Economy

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

January 19, 2026

Income investors can rely on these stocks.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

86 87 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.